+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 37 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.

Age: 18Years +All GendersPhase 3
221 locations
G

Actively Recruiting

Researchers are studying the impact and burden of three skin conditions moderate or severe alopecia areata, non-segmental vitiligo, and moderate to severe hidradenitis suppurativa. The study includes adolescents and adults and aims to understand how these conditions affect quality of life and daily functioning in a large global population. This is an observational study where participants with each condition will have a single visit for data collection following routine clinical practice. No experimental treatments are given instead, the study gathers information during this one visit to assess disease characteristics and impact. During the visit, participants will complete questionnaires and clinical assessments specific to their condition. These include tools measuring symptom impact, hair loss severity, skin depigmentation, and quality of life related to each disease. This helps researchers better understand the real-world burden of these conditions. Participation involves only this one visit, with no long-term follow-up or additional procedures.

Age: 12Years +All Genders
116 locations
P

Actively Recruiting

Researchers are evaluating the combination of calderasib and pembrolizumab as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer NSCLC that has a specific KRAS G12C mutation and a PD-L1 tumor proportion score of 50% or higher. The study aims to determine if this combination improves progression-free survival compared to pembrolizumab with placebo. This is a phase 3 randomized, double-blind trial sponsored by Merck Sharp & Dohme LLC. Participants will receive pembrolizumab 200 mg through intravenous infusion on the first day of each 21-day cycle, continuing for up to 35 cycles. In addition, they will take either calderasib or placebo tablets daily until they meet discontinuation criteria. The study includes two groups one receiving calderasib plus pembrolizumab and the other receiving placebo plus pembrolizumab. No new participants will be offered a second course of pembrolizumab. Throughout the study, participants will undergo various assessments including tumor evaluations by central review to measure progression-free survival, overall survival, and response rates. Quality of life and physical functioning will be monitored using standardized questionnaires up to 24 months. Safety will be tracked by recording adverse events and treatment discontinuations for up to approximately 80 months. The total study duration extends up to 7 years, with ongoing monitoring throughout.

Age: 18Years +All GendersPhase 3
246 locations
E

Actively Recruiting

Researchers are evaluating the effect of E6742, an oral drug, compared with a placebo in adults with systemic lupus erythematosus SLE. This phase 2, randomized, double-blind, placebo-controlled study aims to assess how different doses of E6742 influence the proportion of participants achieving a response using the British Isles Lupus Assessment Group BILAG based Composite Lupus Assessment BICLA while using a low dose of oral corticosteroids at Week 24. Participants will be randomly assigned to receive one of several doses of E6742 or a placebo in oral tablet form. The treatment period involves administering these doses while monitoring participants for up to 24 weeks. The study evaluates the efficacy based on dose response, as well as safety measures including adverse events, laboratory tests, vital signs, and various clinical assessments during this time. Throughout the study, participants will undergo multiple evaluations including clinical assessments like SLEDAI-2K, BILAG-2004, patient-reported outcomes, and laboratory tests such as autoantibody levels and complements. Safety will be monitored via vital signs, ECGs, ophthalmic exams, and chest X-rays. The primary outcome is measured at Week 24, with safety and secondary outcomes assessed up to 52 weeks. Participants are expected to comply with study visits and treatments over this period.

Age: 18Years - 75YearsAll GendersPhase 2
54 locations
R

Actively Recruiting

Researchers are evaluating saruparib AZD5305 added to standard radiation therapy RT and androgen deprivation therapy ADT compared to placebo in men with high-risk and very high-risk localized or locally advanced prostate cancer who have a BRCA1 or BRCA2 gene mutation. This Phase III randomized, double-blind, placebo-controlled study aims to assess whether saruparib improves metastasis-free survival in this specific group of patients. Participants will be divided into two groups Cohort A includes men with newly diagnosed high-risk prostate cancer or high-risk biochemical recurrence after radical prostatectomy, receiving saruparib or placebo with ADT Cohort B includes men with very high-risk prostate cancer receiving saruparib or placebo combined with ADT plus abiraterone and prednisoloneprednisone. Saruparib and placebo are given orally, alongside standard treatments, and participants will receive the treatment and follow-up according to their assigned cohort. During the study, participants will undergo scans including CT or MRI, bone scans, and PSMA-PET to monitor disease status. Researchers will track survival outcomes, metastasis-free survival up to about 93 months, and overall survival up to 11 years. Blood samples will measure drug concentrations, and safety will be monitored through adverse event reporting. Participants will be followed until the study ends, with ongoing assessments to evaluate treatment effects and safety.

Age: 18Years +MALEPhase 3
346 locations
E

Actively Recruiting

Researchers are evaluating the use of nipocalimab in pregnant individuals at risk for severe Hemolytic Disease of the Fetus and Newborn HDFN. The study aims to compare nipocalimab with a placebo to see if it can reduce the risk of fetal anemia, a condition where the babys red blood cell levels drop too low during pregnancy. This phase 3, randomized, placebo-controlled, and triple-blind study is conducted across multiple centers. Participants will receive either nipocalimab or a matching placebo through weekly intravenous infusions starting from randomization until 35 weeks of gestational age. The study groups include an experimental group receiving nipocalimab and a placebo group receiving an inactive treatment, both administered once weekly. The study timeline spans from randomization during weeks 13 to 18 of pregnancy through delivery and includes follow-up through the neonatal period and beyond. Participants will undergo various assessments including lab tests, fetal DNA testing, and monitoring of maternal and neonatal health outcomes. Researchers will measure the percentage of pregnancies without fetal loss, intrauterine transfusions, hydrops fetalis, or neonatal death, among many other maternal and infant health parameters. Follow-up extends to 104 weeks for some infant assessments, including growth and development, while maternal safety and pregnancy complications are also monitored up to 24 weeks postpartum. This comprehensive monitoring aims to capture the effect of nipocalimab on both mother and baby throughout pregnancy and after birth.

Age: 18Years - 45YearsFEMALEPhase 3
69 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of orforglipron in adult women with stress urinary incontinence SUI who are overweight or have obesity. SUI is characterized by leaking urine during activities such as coughing or exercising. This phase 3 study aims to compare orforglipron to a placebo in this specific population. Participants will be randomly assigned to receive either orforglipron or a placebo orally. The study follows a parallel design with double masking and includes two independent groups. Treatment and assessments will occur over approximately 58 weeks, including screening, treatment, and safety follow-up. During the trial, participants will undergo evaluations to measure changes in the frequency of incontinence episodes, body weight, quality of life specific to urinary incontinence, use of continence pads, patient impression of condition, cholesterol levels, and waist circumference from baseline to week 52. Safety monitoring will continue through the follow-up period to assess any treatment-related effects.

Age: 18Years +FEMALEPhase 3
120 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of secutrelvir for treating symptomatic nonhospitalized adults and adolescents with COVID-19 who are at high risk of developing severe disease. This phase 3 trial compares secutrelvir to a placebo to better understand its impact on preventing worsening illness and serious outcomes like hospitalization or death. Participants will be randomly assigned to receive either secutrelvir or a placebo. Both treatments are given orally as tablets. The study includes multiple assessments from baseline through 28 days, and safety monitoring continues up to 24 weeks after treatment. The trial is double-blind, so neither participants nor researchers know who receives the active drug or placebo. During the study, participants will be monitored for COVID-19 symptoms, viral levels, and health status through various measures such as symptom resolution times, medically attended visits, hospitalizations, and quality of life questionnaires. Blood samples will be collected on specific days to analyze drug levels and any side effects. The main outcome is to see how many participants experience worsening illness or serious events within 28 days of starting treatment.

Age: 12Years +All GendersPhase 3
51 locations
E

Actively Recruiting

Researchers are evaluating how efgartigimod affects thyroid function in adults with Graves Disease GD, focusing on its safety, tolerability, and impact on antibody levels and immune response. This Phase 3 study compares efgartigimod with placebo in adults whose GD is not adequately controlled with antithyroid drugs, aiming to better understand its effects on thyroid hormone levels and disease control. Participants will be randomly assigned to receive either efgartigimod PH20 subcutaneous injections via prefilled syringe or placebo during the initial double-blinded treatment period part A and treatmentobservation period part B. Those who respond may continue to an open-label treatmentobservation phase part C receiving efgartigimod. Treatment and observation durations vary, with total participation lasting from approximately 63 to 135 weeks depending on individual response. During the study, participants will undergo regular assessments of thyroid hormone levels fT3, fT4, TSH, antibody levels, and immune responses to evaluate treatment effects. Safety and tolerability will be closely monitored, and researchers will track changes in thyroid-related symptoms and quality of life. The main outcome is the percentage of participants achieving normal thyroid hormone levels without antithyroid drugs by week 24. Participants will be followed for up to nearly three years to observe long-term effects and safety.

Age: 18Years +All GendersPhase 3
51 locations
C

Actively Recruiting

Researchers are evaluating the efficacy and safety of a fixed combination of follitropin alfa and lutropin alfa compared to human menopausal gonadotropin hMG in Japanese women with luteinizing hormone LH and follicle stimulating hormone FSH deficiency undergoing assisted reproductive technology ART. The study focuses on women who are premenopausal and wish to conceive, addressing fertility challenges related to these hormone deficiencies. This is a Phase 3 interventional trial with a randomized, parallel-group design. Participants will be assigned to one of two groups one receiving a fixed combination of recombinant follitropin alfa and lutropin alfa in a 21 ratio, and the other receiving hMG. Both treatments are administered daily by subcutaneous injection during ovarian stimulation, up to 18 days. Additional medications include daily cetrorelix acetate starting on Day 5 or 6 of stimulation to prevent premature ovulation, and coriongonadotropin alfa for final follicular maturation. After oocyte retrieval, participants will self-administer progesterone gel intravaginally for luteal phase support. During the study, participants will undergo assessments such as ultrasound scans to monitor follicle development, hormone level evaluations, and semen analysis of the male partner. Researchers will track the total number of oocytes retrieved, dosage and duration of gonadotropin treatment, embryo development, pregnancy rates, and safety outcomes including adverse events and ovarian hyperstimulation syndrome. The total study duration is about 5.5 months for those not becoming pregnant and up to 13 months for those with confirmed pregnancy.

Age: 18Years - 42YearsFEMALEPhase 3
21 locations

1-10 of 37

1